Hi Nicole

Apologies I inadvertently sent comments on behalf of NLCFN through the link on the NICE website.
NICE Reference: NF-2302-0041126
Please accept this additional summary on behalf of NLCFN.

We agree that testing for EGFR-TK mutation status does occur for most people with a diagnosis of non small cell lung cancer of adenocarcinoma subtype. However, many people with a non small cell lung cancer other than an adenocarcinoma (such as NOS or mixed cell type) do not routinely have access to EGFR-TK testing.
People with a non small cell lung cancer EGFR –TK mutation unknown, who are without access to EGFR-TK testing, do not appear to have been considered within the scope of this recommendation. It is important that these people are not disadvantaged.

We acknowledge that extending survival and improving quality of life are important to people with non small cell lung cancer. Patient's frequently highlight to us when life expectancy is short spending less time in hospital, at hospital appointments, and complications of treatments are key considerations when considering second-line treatment. As the consultation identifies only a small proportion of people are suitable for second-line treatment.

We would like to highlight that the patient experience is often more unpleasant with docetaxel and tolerated far less well than erlotinib

Kind regards

[redacted]

Tel: [redacted]